Research suggests that targeting branched N-glycans and fucosylation may sensitize ovarian tumors to immune checkpoint blockade. This approach may have implications for cancer treatment, although its potential applications and effectiveness in various types of cancer are still being explored. The role of glycosylation and related enzymes in cancer is a subject of ongoing study, with possible connections to immunotherapy responses and therapeutic target discovery.